Cadrenal Therapeutics Files 8-K with Financials

TL;DR

CADX filed an 8-K on 4/9/23 with financials and other disclosures.

AI Summary

On April 9, 2023, Cadrenal Therapeutics, Inc. filed an 8-K report detailing its financial statements and exhibits. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry. The filing also includes information related to Regulation FD Disclosure and Other Events.

Why It Matters

This filing provides investors with updated financial information and disclosures, crucial for understanding the company's current financial health and operational status.

Risk Assessment

Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate significant operational or financial changes.

Key Players & Entities

• Cadrenal Therapeutics, Inc. (company) — Registrant
• April 9, 2023 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 (address) — Principal Executive Offices
• 904-300-0701 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar

Filing Documents

• ea0203558-8k_cadrenal.htm (8-K) — 28KB
• ea020355801ex99-1_cadrenal.htm (EX-99.1) — 10KB
• 0001213900-24-031371.txt ( ) — 214KB
• cvkd-20230409.xsd (EX-101.SCH) — 3KB
• cvkd-20230409_lab.xml (EX-101.LAB) — 33KB
• cvkd-20230409_pre.xml (EX-101.PRE) — 22KB
• ea0203558-8k_cadrenal_htm.xml (XML) — 4KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On April 9, 2024, Cadrenal Therapeutics, Inc. (the "Company") issued a press release announcing that the United States Food and Drug Administration (the "FDA") has granted tecarfarin Orphan Drug Designation for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist device, right ventricular assist device, collectively known as ventricular assist devices, biventricular assist device, and total artificial heart). The information in this Item 7.01 and the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

01 Other Information

Item 8.01 Other Information. On April 9, 2024, the Company announced that the FDA has granted tecarfarin Orphan Drug Designation for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist device, right ventricular assist device, collectively known as ventricular assist devices, biventricular assist device, and total artificial heart).

01. Financial

Item 9.01. Financial (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release date April 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 9, 2024 CADRENAL THERAPEUTICS, INC. By: /s/ Quang Pham Name: Quang Pham Title: Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR